Based on these, we propose the hypothesis that M35L mutation possibly exchanges SPOP substrates from oncoproteins (such as GLI2, c-MYC and TRIM24) to tumor suppressors (such as IRF2BP2), therefore reprogramming the tumor properties of SPOP. Here, IRF2BP2 is linked to neoplasm.